Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Dr Jesse Morse explains why BPC 157 will never receive FDA approval despite its potential to accelerate healing and recovery from injuries. >> More FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner